蛋白质疗法市场－全球产业规模、份额、趋势、机会及预测（按蛋白质功能、产品类型、地区和竞争格局划分，2021-2031年）

全球蛋白质疗法市场预计将从 2025 年的 3,011.9 亿美元成长到 2031 年的 4,474.6 亿美元，复合年增长率达到 6.82%。

这些疗法由生物来源的药理活性物质组成，例如单株抗体或重组激素，旨在取代缺失的蛋白质或靶向特定的疾病标记。市场成长的主要驱动力是全球慢性疾病（例如肿瘤和自体免疫疾病）盛行率的不断上升，这些疾病需要强有力的治疗性介入；此外，生物工程技术的进步也使得合成具有更高疗效的复杂分子成为可能。

然而，由于研发和生产高成本，该领域面临严峻的挑战。生物製药生产的复杂性要求严格的品管和低温运输物流，这导致最终价格较高，并限制了新兴经济体患者的用药途径。为了因应这些经济障碍，美国药品研究与製造商协会（PhRMA）报告称，到2025年，美国将核准70多种生物相似药上市，这表明人们越来越重视克服与成本相关的市场扩张障碍。

市场驱动因素

慢性病和代谢性疾病的日益普遍是全球蛋白质疗法市场的主要驱动力。随着癌症和糖尿病等疾病的蔓延，人们对蛋白质药物所提供的高度特异性治疗方法的需求也日益增长。不断扩大的患者群体与单株抗体和替代疗法的广泛应用密切相关，尤其是在诊断率不断上升的已开发地区。美国癌症协会发布的《2025年癌症事实与数据》报告强调了这一紧迫性，预测到2025年美国将新增超过200万例癌症病例。

同时，有利的法规环境和加速的核准流程正显着加快新型治疗方法的市场准入。监管机构正在推动简化生物製药的审查流程，以满足未被满足的医疗需求，从而缩短研发週期并促进创新。监管事务专业人员协会 (RAPS) 的报告也印证了这一效率，该报告指出，美国食品药物管理局(FDA) 在 2024 年核准了50 种新的分子实体。这种监管支持转化为商业性成功，诺和诺德公司 2025 年的报告便证明了这一点，该报告指出，其基于 GLP-1 的糖尿病治疗产品在 2024 年的销售额将达到 1491 亿丹麦克朗。

市场挑战

全球蛋白质疗法市场面临一个重大障碍：产品研发和生产需要巨额资本投入。与小分子药物不同，蛋白质疗法是体积庞大、结构复杂的生物製药，需要高度专业的生产设施和严格的品质保证通讯协定。这种技术复杂性要求前期投资大量资金，不仅提高了新参与企业的进入门槛，也加剧了现有生产商的资源压力。因此，企业不得不提高产品价格以收回投资，这往往会限制其目标患者群体。

这种经济负担直接阻碍了市场扩张，尤其是在医疗预算紧张、对成本高度敏感的地区。对先进低温运输物流的需求进一步增加了营运成本，使得世界各地许多人难以负担这些救命疗法。欧洲製药工业协会联合会（EFPIA）估计，到2024年，欧洲以研发为基础的製药业将在研发方面投入550亿欧元，如此庞大的投入导致单位成本持续高企，阻碍了整体市场成长，凸显了该产业的资本密集特征。

市场趋势

将人工智慧 (AI) 应用于蛋白质设计，能够开发出具有优化特性的新型疗法，从根本上改变了药物发现流程。与传统筛检方法不同，生成式 AI 模型可以高精度地预测蛋白质结构和结合亲和性，从而显着缩短先导化合物的最佳化週期。这项技术进步正吸引大量投资。根据 BioSpace 2024 年 4 月的报告显示，Xaira Therapeutics 已筹集超过 10 亿美元的资金筹措，并启动运营，致力于开发一个用于功能分子设计的 AI 驱动平台。

此外，抗体药物复合体（ADC）的加速发展代表着癌症治疗领域的重大变革，其技术已从简单的单株抗体发展到高效、强大的载体。现代ADC采用先进的连接子技术，使其细胞毒性有效载荷仅在癌细胞内释放，从而最大限度地提高疗效，同时最大限度地降低全身毒性。这种潜力正在推动策略整合，例如强生公司于2024年3月宣布以约20亿美元收购Ambrx Biopharma，旨在整合其专有的合成生物学平台，用于设计下一代ADC。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球蛋白质疗法市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依蛋白质功能分类（酵素/调节功能、蛋白质诊断、疫苗）
  • 依产品类型（血液凝固因子、促红血球生成素、促卵泡激素、滤泡刺激素、胰岛素、干扰素、单株抗体）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美蛋白质疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲蛋白质疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区蛋白质疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲蛋白质疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲蛋白质疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球蛋白质疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Amgen Inc.
• Eli Lilly and Company.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc.
• Teva Pharmaceutical Industries Ltd
• Bristol-Myers Squibb Company
• AbbVie Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Protein Therapeutics Market is projected to expand from USD 301.19 Billion in 2025 to USD 447.46 Billion by 2031, achieving a CAGR of 6.82%. These therapeutics consist of pharmacologically active substances derived from living organisms, such as monoclonal antibodies and recombinant hormones, which are engineered to replace deficient proteins or target specific disease markers. Market growth is primarily driven by the increasing global prevalence of chronic conditions like oncology and autoimmune disorders that require potent interventions, alongside advancements in bioengineering that enable the synthesis of complex molecules with enhanced efficacy profiles.

Conversely, the sector faces significant challenges due to the high costs associated with development and manufacturing. The complex nature of biologic production demands strict quality control and cold chain logistics, which raises final prices and limits patient access in emerging economies. Reflecting the industry's effort to address these economic barriers, the Pharmaceutical Research and Manufacturers of America reported that there were over 70 approved biosimilars in the United States in 2025, signaling a strong focus on overcoming cost-related impediments to market expansion.

Market Driver

The rising prevalence of chronic diseases and metabolic disorders serves as a major catalyst for the Global Protein Therapeutics Market. As conditions like cancer and diabetes become more widespread, the demand for highly specific interventions provided by protein-based drugs intensifies. This expanding patient pool correlates with a higher utilization of monoclonal antibodies and replacement therapies, particularly in developed regions where diagnosis rates are increasing. Highlighting this urgent need, the American Cancer Society's 'Cancer Facts & Figures 2025' report projected that over 2 million new cancer cases would be diagnosed in the United States in 2025.

Simultaneously, a supportive regulatory environment and accelerated approval pathways are significantly speeding up market entry for new treatments. Regulatory agencies are increasingly adopting streamlined review processes for biologics that address unmet medical needs, reducing development timelines and fostering innovation. This efficiency is evidenced by the Regulatory Affairs Professionals Society's report that the U.S. FDA approved 50 new molecular entities in 2024. Such regulatory support translates into commercial success, as seen in Novo Nordisk's 2025 report, which stated that sales of its GLP-1 based diabetes products reached DKK 149.1 billion in 2024.

Market Challenge

The Global Protein Therapeutics Market confronts a major obstacle regarding the immense capital expenditure needed for product development and manufacturing. Unlike small-molecule drugs, protein therapeutics are large, complex biologics requiring highly specialized production facilities and rigorous quality assurance protocols. This technical complexity demands a massive upfront financial commitment, creating a high barrier to entry for new competitors and straining the resources of existing manufacturers, often forcing companies to set premium prices to recover their investments, which limits the addressable patient population.

This economic strain directly impedes market expansion, especially in cost-sensitive regions with constrained healthcare budgets. The requirement for sophisticated cold chain logistics further increases operational costs, making these life-saving treatments unaffordable for many people globally. The financial intensity of the sector is underscored by the European Federation of Pharmaceutical Industries and Associations, which estimated that the research-based pharmaceutical industry invested €55 billion in research and development in Europe in 2024, an expenditure level that sustains high unit costs and hinders broader market growth.

Market Trends

The integration of Artificial Intelligence into protein design is fundamentally transforming discovery pipelines by allowing for the de novo generation of therapeutics with optimized properties. Unlike traditional screening methods, generative AI models can predict protein structures and binding affinities with high accuracy, significantly shortening lead optimization timelines. This technological advancement has attracted substantial investment, as evidenced by BioSpace's April 2024 report stating that Xaira Therapeutics launched with over $1 billion in committed capital to advance an AI-driven platform for designing functional molecules.

Furthermore, the acceleration of Antibody-Drug Conjugate (ADC) development marks a critical evolution in oncology, progressing from simple monoclonal antibodies to highly potent armed constructs. Modern ADCs employ sophisticated linker technologies to release cytotoxic payloads exclusively within tumor cells, maximizing efficacy while minimizing systemic toxicity. This potential has driven strategic consolidation, exemplified by Johnson & Johnson's March 2024 announcement that it completed the acquisition of Ambrx Biopharma for approximately $2 billion to integrate its proprietary synthetic biology platform for next-generation ADC design.

Key Market Players

• Amgen Inc.
• Eli Lilly and Company.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc.
• Teva Pharmaceutical Industries Ltd
• Bristol-Myers Squibb Company
• AbbVie Inc.

Report Scope

In this report, the Global Protein Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Therapeutics Market, By Protein Function

• Enzymatic & Regulatory
• Protein Diagnostics
• Vaccines

Protein Therapeutics Market, By Product Type

• Blood Clotting Factor
• Erythropoietin
• Follicle Stimulating Hormone
• G-CSF
• Insulin
• Interferons
• Monoclonal Antibodies

Protein Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Therapeutics Market.

Available Customizations:

Global Protein Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines)
  • 5.2.2. By Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone, G-CSF, Insulin, Interferons, Monoclonal Antibodies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Protein Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Protein Function
  • 6.2.2. By Product Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protein Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Protein Function
      • 6.3.1.2.2. By Product Type
  • 6.3.2. Canada Protein Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Protein Function
      • 6.3.2.2.2. By Product Type
  • 6.3.3. Mexico Protein Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Protein Function
      • 6.3.3.2.2. By Product Type

7. Europe Protein Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Protein Function
  • 7.2.2. By Product Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protein Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Protein Function
      • 7.3.1.2.2. By Product Type
  • 7.3.2. France Protein Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Protein Function
      • 7.3.2.2.2. By Product Type
  • 7.3.3. United Kingdom Protein Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Protein Function
      • 7.3.3.2.2. By Product Type
  • 7.3.4. Italy Protein Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Protein Function
      • 7.3.4.2.2. By Product Type
  • 7.3.5. Spain Protein Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Protein Function
      • 7.3.5.2.2. By Product Type

8. Asia Pacific Protein Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Protein Function
  • 8.2.2. By Product Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protein Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Protein Function
      • 8.3.1.2.2. By Product Type
  • 8.3.2. India Protein Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Protein Function
      • 8.3.2.2.2. By Product Type
  • 8.3.3. Japan Protein Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Protein Function
      • 8.3.3.2.2. By Product Type
  • 8.3.4. South Korea Protein Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Protein Function
      • 8.3.4.2.2. By Product Type
  • 8.3.5. Australia Protein Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Protein Function
      • 8.3.5.2.2. By Product Type

9. Middle East & Africa Protein Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Protein Function
  • 9.2.2. By Product Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protein Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Protein Function
      • 9.3.1.2.2. By Product Type
  • 9.3.2. UAE Protein Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Protein Function
      • 9.3.2.2.2. By Product Type
  • 9.3.3. South Africa Protein Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Protein Function
      • 9.3.3.2.2. By Product Type

10. South America Protein Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Protein Function
  • 10.2.2. By Product Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protein Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Protein Function
      • 10.3.1.2.2. By Product Type
  • 10.3.2. Colombia Protein Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Protein Function
      • 10.3.2.2.2. By Product Type
  • 10.3.3. Argentina Protein Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Protein Function
      • 10.3.3.2.2. By Product Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protein Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Amgen Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eli Lilly and Company.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Johnson & Johnson Services, Inc
• 15.5. Merck KGaA
• 15.6. Pfizer Inc.
• 15.7. AstraZeneca Plc.
• 15.8. Teva Pharmaceutical Industries Ltd
• 15.9. Bristol-Myers Squibb Company
• 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer